HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

yttrium 90-DOTA-lanreotide

Also Known As:

90Y-DOTA-lanreotide

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- yttrium 90-DOTA-lanreotide: 4
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - yttrium 90-DOTA-lanreotide: 4
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - yttrium 90-DOTA-lanreotide: 4

Experts

1.	Buscombe, John R: 1 article (11/2005)
2.	Caplin, Martyn E: 1 article (11/2005)
3.	Maudgil, Dave: 1 article (11/2005)
4.	McStay, Mary K G: 1 article (11/2005)
5.	Tibballs, Jonathan M: 1 article (11/2005)
6.	Watkinson, Anthony F: 1 article (11/2005)
7.	Williams, Martin: 1 article (11/2005)
8.	Andreae, F: 1 article (06/2001)
9.	Angelberger, P: 1 article (06/2001)
10.	Dudczak, R: 1 article (06/2001)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2001 - "The study "MAURITIUS" (MulticenterAnalysis of a Universal Receptor Imaging and Treatment Initiative, a eUropean Study), a Phase IIa study, showed in patients with a calculated tumor dose >10 Gy/GBq 90Y-DOTA-lanreotide, the proof-of-principle for treating tumor patients with receptor imaging agents. " 06/01/2001 - "Based on its unique hSSTR binding profile, 111In-DOTA-lanreotide was suggested to be a potential radioligand for tumor diagnosis, and 90Y-DOTA-lanreotide suitable for receptor-mediated radionuclide therapy. " 11/01/1998 - "Indium-111 -DOTA-lanreotide was then administered to 14 cancer patients evaluated for possible radiotherapy with 90Y-DOTA-lanreotide (8 neuroendocrine tumors, 4 intestinal adenocarcinomas, 1 Hodgkin lymphoma and 1 prostate cancer). "
2.	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/01/2005 - "Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy." 11/01/1998 - "Indium-111 -DOTA-lanreotide was then administered to 14 cancer patients evaluated for possible radiotherapy with 90Y-DOTA-lanreotide (8 neuroendocrine tumors, 4 intestinal adenocarcinomas, 1 Hodgkin lymphoma and 1 prostate cancer). "
3.	Gastrinoma 12/01/1998 - "We report the case of a patient with metastatic gastrinoma who was treated with 90Y-DOTA-lanreotide. " 12/01/1998 - "Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma." 12/01/1998 - "After four infusions of 90Y-DOTA-lanreotide (each 1 GBq, approximately 30 nmol) over a 6-mo period, the 111In-DOTA-lanreotide scintigraphy of the liver had returned to a nearly normal condition and a remarkably decreased uptake by the recurrent gastrinoma was calculated (approximately 5 mGy/MBq for 90Y-DOTA-lanreotide). "
4.	Prostatic Neoplasms (Prostate Cancer) 11/01/1998 - "Indium-111 -DOTA-lanreotide was then administered to 14 cancer patients evaluated for possible radiotherapy with 90Y-DOTA-lanreotide (8 neuroendocrine tumors, 4 intestinal adenocarcinomas, 1 Hodgkin lymphoma and 1 prostate cancer). "
5.	Neoplasm Metastasis (Metastasis) 11/01/2005 - "Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy."

Related Drugs and Biologics

1.	indium 111-DOTA-lanreotide
2.	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
3.	lanreotide (Somatuline)
4.	Radioisotopes (Radionuclides)
5.	Indium-111

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Palliative Care (Palliative Therapy)